RGS16 and Patent ductus arteriosus: In a proof-of-principle for drug screens, we find that weanling KIC mice with PDA treated with the standard-of-care combination of gemcitabine and nab-paclitaxel (Abraxane) (Masellis et al., 2009; Frese et al., 2012; Von Hoff et al., 2013; Neesse et al., 2014) for 2 weeks have significantly lower Rgs16::GFP expression, and reduced tumor size and occurrence.